Stathmin 1 (STMN1) (STMN1)

Stathmin 1 (STMN1), also known as Oncoprotein 18, is a highly conserved cytosolic phosphoprotein that serves as a key regulator of microtubule dynamics [1, 2]. It functions by either sequestering tubulin heterodimers or directly promoting the depolymerization of microtubules, processes that are essential for the assembly and disassembly of the mitotic spindle during the cell cycle [3]. STMN1 is frequently overexpressed in a wide range of human cancers, including hepatocellular carcinoma, breast cancer, and lung cancer, where its high levels are associated with aggressive tumor behavior and poor patient outcomes [5]. Because of its pivotal role in cell proliferation, STMN1 mRNA is a significant therapeutic target for RNA-based interventions such as small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) [4]. These strategies aim to knock down STMN1 expression, thereby inducing mitotic arrest and apoptosis in malignant cells [5]. Clinical development has explored siRNA-based delivery systems, such as DCR-STMN1, though challenges such as efficient tumor-specific delivery and potential toxicity to normal proliferating tissues remain areas of active research [4].

Other names

Oncoprotein 18Op18LAP18LagMetablastinPR22pp19

RNA interference (RNAi) leading to the sequence-specific degradation of STMN1 mRNA, which results in the depletion of stathmin 1 protein, disruption of mitotic spindle assembly, and induction of cell cycle arrest and apoptosis [4, 5].